期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

前列腺癌肿瘤标志物的研究进展 被引量：5

下载PDF
导出
摘要 前列腺癌(prostatic carcinoma,PCa)的诊治极大地得益于肿瘤标记物的发现和运用,近年研究较多的PCa肿瘤标志物有:α-甲酰基辅酶A消旋酶(Afpha-methlacryl-Coa racemase,AMACR,P504S)、前列腺特异性膜抗原(prostate-specific membrane,PSMA)、前列腺干细胞抗原(prostate stem cell antigen,PSCA)、DD3基因(PCA3)、人类腺体激肽释放酶-2(hK2)、前列腺特异性抗原(prostate-specific antigen,PSA)、uPA。应用于临床的只有PSA。分子肿瘤学领域中的革新和发现可能给我们提供更加灵敏和特异的可靠的PCa肿瘤标志物。
作者 张海生 覃展偶
机构地区 桂林医学院附属医院泌尿外科
出处 《现代医药卫生》 2011年第19期2933-2935,共3页 Journal of Modern Medicine & Health
关键词 前列腺癌 肿瘤标志物
分类号 R73 [医药卫生—肿瘤]
  • 相关文献

参考文献29

  • 1Jemal A ,Siege R ,Ward E, et al.Cancer statistics[J].2008 CA Cancer J Clin 2008 58(2):71.
  • 22005年上海市恶性肿瘤发病率[J].上海预防医学,2008,20(8):421-422. 被引量：18
  • 3Luo J,Zha S,Gage WR,et al.α-M ethylacyl-CoA racemase a new molecular marker for prostate cancer[J].Cancer Res, 2002,62(8):2220.
  • 4姚宏.前列腺癌p504s标记物研究最新进展[J].山西医药杂志,2004,33(8):635-636. 被引量：5
  • 5Jiang Z,W oda BA,Rock KL,et al.P504S a new molecular marker fou the detdction of prostate carcinoma [J].Am J Surg Pathol,2001, 25(11) : 1397.
  • 6Zhou M ,Chinnaiyan AM ,Kleer CG ,et al.Alpha-methylacyl-CoA racemase: a novel tumormarker overexpressed in several human cancers and their precursor lesions[J].Am J Surg Patho1,2006,26(7) :926.
  • 7徐伟,陶志华,王彩虹,翁志梁,吴秀玲,李澄棣,陈占国,陈晓东.尿AMACR mRNA定量检测在前列腺癌诊断中的价值[J].中国男科学杂志,2008,22(2):15-19. 被引量：6
  • 8Murphy GP,Elgamal AA,Su SL,et al.Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen[J].Cancer, 1998,83(11) :2259.
  • 9Kularatne SA,Wang K,Santhapuram HK,et al.Prostatespecific membrane antigen targeted imaging and therapy of prostate cancerusing a PSMA inhibitor as a homin ligand[J].Mol-Pharm, 2009,6(3) :780.
  • 10Yao V, Parwani A, Maier C, et al.Moderate expression of prostate specific membrane antigen, a tissue differentiation antigen and folate hydrolase,facilitates prostate carcinogenesis[J].Cancer Res, 2008,68(21) :9070.

二级参考文献29

  • 1[1]Haese AC, Noldus J. Human Glandular Kallikrein2:A Potential Serum for Predicting the Organ Confined Versus Non-organ Confined Growth of Prostate Cancer[J]. Urol,2000,163:1491～1497.
  • 2[2]Becker F. Human Glandular Kallikrein2:a Tool to Improve Discrimination of Poorly Differentiated and Non-organ-confined Prostate Cancer Compared with Prostate Specific Antigen[J]. Urology,2000,55(4):481～485.
  • 3[3]蒋成淦.酶免疫测定法[M].北京:人民卫生出版社,1985.178.
  • 4[5]陶义训.免疫学和免疫学检验(第2版)[M].北京:人民卫生出版社,2000.150～152.
  • 5[7]Kwiatkowski MK, Becker F. Inprostatism Patients the Ratio of Human Glandular Kallikrein to Free PSA Improves the Discrimination between Prostate Cancer and Benign Prostatic Hyperplasia within the Diagnostic "Grey Zone" of Total PSA 4～10 ng/L[J]. Urology,1998,51:360～365.
  • 6[8]Finlay JA, Eveans CL, Day JR, et al. Development of Monoclonal Antibodies Specific for Human Glandular Kallikrein2[J]. Urology,1998,51:159～178.
  • 7[9]Nam RK, Diancondis EP. Serum Human Glandular Kallikrein2 Prostate Levels Predict the Presense of Prostate Cancer among Men with Elevated Prostate Specific Antigen(PSA)[J]. Clin Oncol,2000,18:1036～1042.
  • 8[10]Magklara A, Scorilas A. The Combination of Human Glandular Kallikrein2 and Free Prostate Specific Antigen(PSA) and Benign Prostatic Hyperplasia in Patients with Moderatedly Increased Total PSA[J]. Clin Chem,1999,45:1961～1966.
  • 9Jiang X. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res, 2000,60:1677-1682.
  • 10Rubin MA. α-Methylacyl-CoA racemase as a tissue biomarker for protate cancer. JAMA,2002,287(13) :1662-1670.

共引文献30

同被引文献44

引证文献5

二级引证文献22

现代医药卫生
2011年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部